These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

230 related items for PubMed ID: 27040634

  • 1. Evaluation of Antiemetic Therapy for Hepatic Transcatheter Arterial Infusion Chemotherapy with Cisplatin.
    Hashizume J, Higuchi N, Sato K, Kodama Y, Matsunaga N, Sakamoto T, Yamaguchi K, Nakamura T, Kitahara T, Sasaki H.
    Biol Pharm Bull; 2016; 39(4):611-4. PubMed ID: 27040634
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H, Yamamoto N, Shirai T, Nishida H, Hayashi K, Tanzawa Y, Takeuchi A, Igarashi K, Inatani H, Shimozaki S, Kato T, Aoki Y, Higuchi T, Tsuchiya H.
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [Abstract] [Full Text] [Related]

  • 3. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
    Gao HF, Liang Y, Zhou NN, Zhang DS, Wu HY.
    Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of the efficacy of palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K, Fushida S, Kaji M, Takeda T, Yabushita K, Nezuka H, Kinami S, Kadoya N, Takai Y, Tsukioka Y, Ohyama S, Tsuji K, Tsukada T, Kinoshita J, Fujimura T, Ohta T.
    Int J Clin Oncol; 2016 Jun; 21(3):483-90. PubMed ID: 26507140
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Palonosetron with aprepitant plus dexamethasone to prevent chemotherapy-induced nausea and vomiting during gemcitabine/cisplatin in urothelial cancer patients.
    Kitamura H, Takahashi A, Hotta H, Kato R, Kunishima Y, Takei F, Horita H, Masumori N, Sapporo Medical University Urologic Oncology Consortium.
    Int J Urol; 2015 Oct; 22(10):911-4. PubMed ID: 26087891
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, placebo-controlled, phase III cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study.
    Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH.
    J Clin Oncol; 2012 Nov 10; 30(32):3998-4003. PubMed ID: 22915652
    [Abstract] [Full Text] [Related]

  • 8. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
    Navari RM.
    J Support Oncol; 2003 Nov 10; 1(2):89-103. PubMed ID: 15352652
    [Abstract] [Full Text] [Related]

  • 9. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S.
    Lancet Oncol; 2009 Feb 10; 10(2):115-24. PubMed ID: 19135415
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI, Lee DE, Cho I, Yoon JH, Yoon SS, Lee HS, Oh JM.
    Ann Pharmacother; 2012 Dec 10; 46(12):1637-44. PubMed ID: 23170032
    [Abstract] [Full Text] [Related]

  • 11. New antiemetic drugs.
    Roila F, Fatigoni S.
    Ann Oncol; 2006 Mar 10; 17 Suppl 2():ii96-100. PubMed ID: 16608997
    [Abstract] [Full Text] [Related]

  • 12. QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist.
    Liu J, Tan L, Zhang H, Li H, Liu X, Yan Z, Chen J, Yang H, Zhang D.
    Eur J Cancer Care (Engl); 2015 May 10; 24(3):436-43. PubMed ID: 25404537
    [Abstract] [Full Text] [Related]

  • 13. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S, Buchner D, Craver C, Gayle J.
    Clin Ther; 2011 Apr 10; 33(4):443-55. PubMed ID: 21635990
    [Abstract] [Full Text] [Related]

  • 14. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
    Oyama K, Fushida S, Kaji M, Takeda T, Kinami S, Hirono Y, Yoshimoto K, Yabushita K, Hirosawa H, Takai Y, Nakano T, Kimura H, Yasui T, Tsuneda A, Tsukada T, Kinoshita J, Fujimura T, Ohta T.
    J Gastroenterol; 2013 Nov 10; 48(11):1234-41. PubMed ID: 23338487
    [Abstract] [Full Text] [Related]

  • 15. Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
    Yang CK, Wu CE, Liaw CC.
    Biomed J; 2016 Feb 10; 39(1):60-6. PubMed ID: 27105599
    [Abstract] [Full Text] [Related]

  • 16. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
    Matsui R, Suzuki K, Takiguchi T, Nishio M, Koike T, Hayashi T, Seto T, Kogure Y, Nogami N, Fujiwara K, Kaneda H, Harada T, Shimizu S, Kimura M, Kenmotsu H, Shimokawa M, Goto K.
    BMC Pharmacol Toxicol; 2020 Oct 06; 21(1):72. PubMed ID: 33023657
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
    Shi Q, Li W, Li H, Le Q, Liu S, Zong S, Zheng L, Hou F.
    Oncotarget; 2016 Apr 26; 7(17):24402-14. PubMed ID: 27015550
    [Abstract] [Full Text] [Related]

  • 19. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
    Hsu ES.
    Am J Ther; 2010 Apr 26; 17(5):476-86. PubMed ID: 20844345
    [Abstract] [Full Text] [Related]

  • 20. [A randomized crossover comparison of azasetron and granisetron in the prophylaxis of emesis induced by chemotherapy including cisplatin].
    Tsukuda M, Mochimatsu I, Furukawa M, Kohno H, Kawai S, Enomoto H, Yago T, Matsuda H, Ikema Y, Zhou L.
    Gan To Kagaku Ryoho; 1995 Nov 26; 22(13):1959-67. PubMed ID: 7487127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.